Skip to content
lifestyle.ukuncut.org.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Moderna, Inc.
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
August 5, 2026
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna’s Investigational Vaccine Against Bundibugyo Ebolavirus
August 4, 2026
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
July 31, 2026
Moderna Science Day Highlights Expanding Potential of mRNA Platform
June 25, 2026
Moderna to Present at Upcoming Conference in June 2026
June 2, 2026
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
June 1, 2026
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
June 1, 2026
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
June 1, 2026
Moderna Recognized by TIME as One of the World’s Most Impactful Companies
May 12, 2026
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
May 6, 2026
1
2
3
Next Page
→